trial · primary record
Ticagrelor: an oral, direct-acting, reversibly binding P2Y12 receptor antagonist
Chronic Kidney Disease (CKD)
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 230 |
| Primary completion | 2031-07 |
| Primary endpoint | Aim 1: post-treatment IL-1β value |
| Registry ID | NCT07911124 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:43:29.715Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07911124
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.